Core Viewpoint - Furuya Medical Technology (01696) has seen a stock price increase of over 6%, currently trading at 5.98 HKD with a transaction volume of 10.9752 million HKD, following the announcement of a commercial distribution cooperation agreement with Fosun Wanbang [1] Group 1: Company Developments - Furuya Medical Technology has entered into a commercial distribution cooperation agreement with Fosun Wanbang, which will provide services for the product Botulinum Toxin Type A, marketed as Daxifei in mainland China [1] - The agreement includes commercialization, marketing, medical education, and business planning services, with an annual transaction cap of 17 million USD for this year and the next [1] - The product is designed to temporarily improve moderate to severe frown lines caused by the activity of the glabellar and/or corrugator muscles in adults [1]
港股异动 | 复锐医疗科技(01696)涨超6% 与复星万邦(江苏)订立商业配送合作协议